OMH Osmetech

Osmetech (LSE:OMH) today announced that it has submitted a request to the US FDA for Emergency Use Authorization (EUA) for its Respiratory Pathogen Test Panel test to be used to screen for the swine flu virus.

Osmetech�s Respiratory Pathogen Test Panel test, which is expected to be launched as a research use only (RUO) product next quarter, detects and differentiates between 18 common bacterial and viral infections, including the Influenza A virus and its H1N1 subtype. Osmetech is currently developing an extension to the Respiratory Pathogen Test that will differentiate this H1N1 subtype between the human and swine forms of the virus.

Osmetech Respiratory Pathogen Test Panel test has been adapted from QIAGEN�s QIAplex-based respiratory viral test for use on Osmetech�s eSensor XT-8 molecular diagnostics system, under the terms of an agreement signed in September 2008.

James White, Chief Executive, Osmetech plc, said:

"We believe that our test is ideally suited for fast and reliable screening of Influenza A virus types, including the swine flu strain which is currently a major pandemic concern. The test will be run on our eSensor XT-8 platform, which is a small, portable and easy to use platform that has the potential to enable testing to occur in numerous locations."

About Swine Flu:

Swine flu (swine influenza) is a highly contagious respiratory disease of pigs, caused by one of several swine influenza A viruses. Since pigs can be infected with more than one virus type at a time, genes of several viruses from various sources (including humans) can mix, allowing the swine influenza viruses to cross species barrier and eventually cause disease in humans. The clinical symptoms then are similar to seasonal influenza and other acute upper respiratory tract infections, in some cases leading to severe pneumonia and resulting in death. However, since mild or asymptomatic cases may have escaped from recognition, the true extent of this disease among humans is still unknown. Currently, there is no human vaccine on the market which protects against swine influenza. Antiviral drugs are available in many countries. More information on the swine flu is available on http://www.who.int/.

About Osmetech plc (www.osmetech.com)

Osmetech plc is an AIM-listed public company on the London Stock Exchange. The Company is a fast developing, international diagnostics business with operations in Boston and Pasadena in the US, serving the high growth molecular diagnostic market targeting hospitals and reference laboratories.

Osmetech has a strong portfolio of over 200 issued and pending patents and has launched its first generation eSensor 4800 platform, an electrochemistry-based array system, together with an FDA cleared in vitro diagnostic test for Cystic Fibrosis carrier detection.

Osmetech�s second generation platform, the eSensor XT-8 received FDA 510(k) clearance in July 2008 together with our eSensor Warfarin Sensitivity Test. These products are now being marketed in the U.S. together with a 2C9 Genotyping Test for drug metabolism and a Cystic Fibrosis carrier detection test which are both available for research use purposes only.

In April 2009, Osmetech signed a five-year distribution agreement with Fisher HealthCare, a part of Thermo Fisher Scientific, whereby Fisher HealthCare will distribute Osmetech�s eSensor XT-8 instrument platform and molecular diagnostic tests and consumables in the U.S.

The eSensor XT-8 System is designed to support a broad menu of tests and Osmetech has scheduled for commercial launch a number of further tests including: extended warfarin panel with the proprietary 4F2 marker, venous thrombosis (Factor II, Factor V Leiden and MTHFR) and the RESPLEX II respiratory pathogen assay in-licensed from Qiagen. The System provides accurate results while minimizing technician involvement and its features compare favorably to those of other molecular detection systems. Its ease of use, readily interpretable results, speed and low maintenance are particularly suited to the needs of the decentralizing market.

Osmetech (LSE:OMH)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025

Osmetech (LSE:OMH)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025